• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.73% Nasdaq Down0.96%

    INSYS Therapeutics, Inc. (INSY)

    42.79 Down 0.55(1.27%) 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    INSYS Therapeutics, Inc.
    1333 South Spectrum Boulevard
    Suite 100
    Chandler, AZ 85286
    United States - Map
    Phone: 480-500-3127
    Fax: 602-910-2627
    Website: http://www.insysrx.com

    Index Membership:N/A
    Full Time Employees:382

    Business Summary 

    Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Its products candidates also include Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. The company is headquartered in Chandler, Arizona.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on INSYS Therapeutics, Inc.

    Corporate Governance 
    INSYS Therapeutics, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 10; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. John N. Kapoor Ph.D., 71
    Co-Founder and Exec. Chairman
    Mr. Michael L. Babich , 38
    Chief Exec. Officer, Pres and Director
    Mr. Darryl S. Baker , 46
    Chief Financial Officer
    Mr. Franc Del Fosse , 43
    Gen. Counsel and Corp. Sec.
    Venkat Goskonda Ph.D.,
    Sr. Director of Pharmaceutical Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders